 |
 |
I initially saw the info on Amgen in the newspaper Investor's Business Daily. Amgen reported that the drug is of a family of compounds called neuroimmunophilins for treating brain disorders such as parkinson's disease which in preclinical studies demonstrated the potential to regenerate and repair damaged nerve cells. I called Amgen and spoke with staff in Profesional services and received more information. I contacted Barb Patterson and she researched it further. We are definitely at a TURNING POINT...